{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-23-000039","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.871166+00:00","generated_at":"2026-06-15T12:08:50.222294+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeoGenomics Q1 revenue up 17% to $137M; narrows net loss; raises FY2023 guidance","bullets":["Consolidated revenue $137M (+17% YoY); Clinical +16% to $115M, Pharma +22% to $22M.","Net loss improved to $31M from $49M; Adjusted EBITDA loss narrowed to $7M from $19M.","FY2023 revenue guidance raised to $555-$565M from $545-$555M; Adj. EBITDA loss guidance improved to $(22)-$(18)M.","Cash and marketable securities $418M; adjusted gross profit margin 43.5%.","Clinical test volume +7% YoY; revenue per test +8% to $402."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-23-000039","json":"https://secwatch.observer/filing/0001077183-23-000039.json","markdown":"https://secwatch.observer/filing/0001077183-23-000039.md","text":"https://secwatch.observer/filing/0001077183-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/0001077183-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/neo-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:08:50.222294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd02b1e30693984cdbd1fd21d9c5dc3ae0e852c5","claim":"NEOGENOMICS INC reported first quarter of 2023 results: revenue $137 million, net income $31 million.","evidence_excerpt":"First-Quarter Results Consolidated revenue for the first quarter of 2023 was $137 million, an increase of 17% over the same period in 2022. Clinical Services revenue of $115 million was an increase year-over-year of 16%. Clinical test volume (1) increased by 7% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 8% to $402. Pharma Services revenue increased by 22% to $22 million compared to the first quarter of 2022. Consolidated gross profit for the first quarter of 2023 was $54.8 million, an increase of 43.4% compared to the first quarter of 2022. This increase was primarily due to an increase in revenue partially offset by higher payroll and payroll-related costs and an increase in supplies expense. Consolidated gross profit margin, including amortization of acquired Inivata developed technology intangible assets, was 39.9%. Adjusted Gross Profit Margin (2) , excluding amortization of acquired Inivata developed technology intangible assets, was 43.5%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/0001077183-23-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$137 million"},{"label":"Net income","value":"$31 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}